Sudha S Murthy
Also known as: SS Murthy ,S Sudha, Sudha Surisetti, Sudha Surisetti Murthy
Krishna Institute of Medical Sciences, Nucleome Informatics Pvt Ltd, Green Templeton College, University of Oxford, Harvard Medical School, Yoda Lifeline Diagnostics, Indian School of Business
About
An Oncopathologist and healthcare management professional with special interest in anatomic pathology, molecular oncology, liquid biopsy, AI and wishes to leverage its potential in the world of precision oncology. Wish to be a part of the momentum of making non invasive solutions for cancer diagnosis ,management and monitoring accessible and affordable to everyone
Employment
-
Krishna Institute of Medical Sciences Director2026 - Present
-
Nucleome Informatics Pvt Ltd Director2025 - 2026
-
Yoda Lifeline Diagnostics Lab Director & HOD,Histopathology & Genomics2023 - 2025
-
Datar Cancer Genetics (India) Director(Clinical Support)2020 - 2023
-
Basavatarakam Indo American Cancer Hospital & Research Institute Chief of Pathology & Lab Medicine2003 - 2020
-
Basavatarakam Indo-American Cancer Hospital and Research Institute Consultant2001 - 2002
-
Nizam's Institute of Medical Sciences Registrar2000 - 2000
Education
-
Green Templeton College, University of Oxford MSc Precision Cancer Medicine2023 - 2025
-
Harvard Medical School HMX Pro-Immunology and Immuno- Oncology2020 - 2020
-
Harvard Medical School HMX Pro Genetics -Cancer Genomics & Precision Oncology2020 - 2020
-
Indian School of Business Advanced Management Programme in Healthcare2016 - 2016
-
National Board of Examinations Dip.NB1998 - 2001
-
Nizam's Institute of Medical Sciences MD1997 - 2000
-
Andhra Medical College MBBS1987 - 1992
Projects & Funding
Projects & funding information is unavailable.
Publications (90)
- Accuracy of Tumor Bed Biopsy for Predicting Pathologic Complete Response After Chemotherapy Among Women With Breast Cancer: Complete Responders in the Breast Study Save
- 1228P A circulating tumor cell (CTC) based assay for diagnostic immunocytochemistry profiling of lung cancer Save
- Circulating tumor cell assay to non-invasively evaluate PD-L1 and other therapeutic targets in multiple cancers Save
- Accurate Prostate Cancer Detection based on Circulating Tumor Cell Profiling Save
- Frequency of Nucleophosmin 1 Expression by Immunohistochemistry in Acute Myeloid Leukemia Save
- Accuracy of digital mammography, ultrasound and MRI in predicting the pathologic complete response and residual tumor size of breast cancer after completion of neoadjuvant chemotherapy. Save
- Sensitivity and specificity of cluster differentiation and friend leukemia integration1 for the diagnosis in a series of molecularly confirmed ewing sarcoma family of tumors Save
- Concordancy of immunocytochemistry profiling of circulating tumor cells with immunohistochemistry for analysis of therapeutically relevant biomarkers Save
- Central nervous system manifestations of hematological malignancies: Our spectrum over 3 years Save
- FISH for EWSR1 in Ewing's sarcoma family of tumors: Experience from a tertiary care cancer center Save